Patents by Inventor Herman Rutner
Herman Rutner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10161934Abstract: Biosensor components (chips) are described based on direct biocoating processes that result in the tenacious and stable, noncovalent (believed to be chemisorptive) binding of anchor substances such as avidin(s) other proteins having specific binding partners or oligo- or poly-nucleotides onto any piezo-electrically active crystal surface. The resulting platform technology can be developed for a variety of biosensors with specific applications in biological assays. The table mono layers of the anchor substances forms reactive layers, ready to bind a capture reagent such as a biot-inylated antibody for capture and detection of analytes in biologic fluid samples.Type: GrantFiled: August 27, 2012Date of Patent: December 25, 2018Assignee: Aviana Molecular Technologies, LLCInventors: Lisa Laury-Kleintop, Herman Rutner
-
Publication number: 20150111765Abstract: Biosensor components (chips) are described based on direct biocoating processes that result in the tenacious and stable, noncovalent (believed to be chemisorptive) binding of anchor substances such as avidin(s) other proteins having specific binding partners or oligo- or poly-nucleotides onto any piezo-electrically active crystal surface. The resulting platform technology can be developed for a variety of biosensors with specific applications in biological assays. The table mono layers of the anchor substances forms reactive layers, ready to bind a capture reagent such as a biot-inylated antibody for capture and detection of analytes in biologic fluid samples.Type: ApplicationFiled: August 27, 2012Publication date: April 23, 2015Applicant: AVIANA MOLECULAR TECHNOLOGIES, LLC.Inventors: Lisa Laury-Kleintop, Herman Rutner
-
Patent number: 8337755Abstract: The present invention provides a protocol and apparatus for enriching circulating tumor cells and other rare cells from blood, including debris and other components, from samples with high precision and at high throughput rates. This invention discloses an improved processing system from previously described semi-automated sample processing. The system further reduces operator intervention and hands-on time from prior systems. While this system has general utility in processing diverse materials, the system is configured for sample processing of biological specimens to provide an enriched fraction suitable for detection, enumeration and identification of target cells by appropriate analytical methodologies.Type: GrantFiled: March 13, 2006Date of Patent: December 25, 2012Assignee: Veridex, LLCInventors: Teresa Bendele, Thomas Harbart, Dave Howard, Michael Kagan, Douglas Keene, Dave Lapeus, Jared Mayes, Douglas Paynter, Jerry Prohaska, Herman Rutner
-
Patent number: 8329422Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CELLSPOTTER® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.Type: GrantFiled: November 2, 2010Date of Patent: December 11, 2012Assignee: Veridex LLCInventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
-
Publication number: 20110136262Abstract: An integrated multiplexed acoustic wave biosensor chip system with enhanced sensitivity has been developed. The biosensor system incorporates one or more microfluidic channels, coated with target-specific binding films enabling rapid and early detection of viral, bacterial or parasitic targets such as Dengue virus and sexually transmitted diseases in specimens from potentially infected patients. The biosensors are used in portable analytical systems that are suitable for real-time point of care (POC) clinical diagnosis in cost sensitive and/or resource limited settings. The highly sensitive biosensors utilize thinned single crystal piezoelectric substrates that propagate layer guided shear horizontal acoustic plate mode (LG-SH-APM) waves in sensing regions bearing immobilized binders that provide simultaneous and direct detection of mass changes due to multiple bound target pathogens or molecules.Type: ApplicationFiled: May 28, 2010Publication date: June 9, 2011Inventors: Vanaja Vijaya Ragavan, Avijit Roy, Herman Rutner
-
Publication number: 20110104718Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.Type: ApplicationFiled: November 2, 2010Publication date: May 5, 2011Applicant: VERIDEX, LLCInventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W.M.M. Terstappen, Shawn Mark O'Hara, Steven Gross
-
Patent number: 7863012Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.Type: GrantFiled: February 17, 2004Date of Patent: January 4, 2011Assignee: Veridex, LLCInventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
-
Patent number: 7282350Abstract: Methods and kits for used as an internal or external control in rare cell analysis are disclosed. A plurality of fluorescently distinct sets of cells is used to define a range to assess the isolation of rare target cells from a sample. Thus, a known number of cells, expressing the surface and intracellular antigens present in the targeted rare cells, are stabilized and modified in such a way that they can be discriminated from the targeted rare cells. In addition, these cells are separated into at least two sets based upon the number. These sets are detectably distinct from each other and provide an upper and lower indication of the detection ability of the rare cell assay.Type: GrantFiled: November 12, 2003Date of Patent: October 16, 2007Assignee: Immunivest CorporationInventors: Galla Chandra Rao, Herman Rutner
-
Publication number: 20070212698Abstract: The present invention provides a protocol and apparatus for enriching circulating tumor cells and other rare cells from blood, including debris and other components, from samples with high precision and at high throughput rates. This invention discloses an improved processing system from previously described semi-automated sample processing. The system further reduces operator intervention and hands-on time from prior systems. While this system has general utility in processing diverse materials, the system is configured for sample processing of biological specimens to provide an enriched fraction suitable for detection, enumeration and identification of target cells by appropriate analytical methodologies.Type: ApplicationFiled: March 13, 2006Publication date: September 13, 2007Inventors: Teresa Bendele, Thomas Harbart, Dave Howard, Michael Kagan, Douglas Keene, Dave Lapeus, Jared Mayes, Douglas Paynter, Jerry Prohaska, Herman Rutner
-
Publication number: 20060194192Abstract: Compositions and methods for stabilizing rare cells in blood specimens, preserving the quality of blood specimens, and also serving as cell fixatives are disclosed which minimize losses of target cells (for example, circulating tumor cells) and formation of debris and aggregates from target cells, non-target cells and plasma components, thereby allowing more accurate analysis and classification of circulating tumor cells (CTC) and, ultimately, of tumor burdens in cancer patients. Stabilization of specimens is particularly desirable in protocols requiring rare cell enrichment from blood specimens drawn from cancer patients. Exposure of such specimens to potentially stressful conditions encountered, for example, in normal processing, mixing, shaking, delays due to transporting the blood, has been observed to not only diminish the number of CTC but also to generate debris and aggregates in the blood specimens that were found to interfere with accurate enumeration of target cells, if present.Type: ApplicationFiled: April 28, 2006Publication date: August 31, 2006Inventors: Galla Rao, Melissa Herman, Herman Rutner, Leon Terstappen
-
Publication number: 20050181353Abstract: Compositions and methods for stabilizing rare cells in blood specimens, preserving the quality of blood specimens, and also serving as cell fixatives are disclosed which minimize losses of target cells (for example, circulating tumor cells) and formation of debris and aggregates from target cells, non-target cells and plasma components, thereby allowing more accurate analysis and classification of circulating tumor cells (CTC) and, ultimately, of tumor burdens in cancer patients. Stabilization of specimens is particularly desirable in protocols requiring rare cell enrichment from blood specimens drawn from cancer patients. Exposure of such specimens to potentially stressful conditions encountered, for example, in normal processing, mixing, shaking, delays due to transporting the blood, has been observed to not only diminish the number of CTC but also to generate debris and aggregates in the blood specimens that were found to interfere with accurate enumeration of target cells, if present.Type: ApplicationFiled: February 17, 2004Publication date: August 18, 2005Inventors: Galla Rao, Melissa Herman, Herman Rutner, Leon Terstappen
-
Publication number: 20050181463Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.Type: ApplicationFiled: February 17, 2004Publication date: August 18, 2005Inventors: Galla Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon Terstappen, Shawn O'Hara, Steven Gross
-
Publication number: 20040072269Abstract: Methods and kits for used as an internal or external control in rare cell analysis are disclosed. A plurality of fluorescently distinct sets of cells is used to define a range to assess the isolation of rare target cells from a sample. Thus, a known number of cells, expressing the surface and intracellular antigens present in the targeted rare cells, are stabilized and modified in such a way that they can be discriminated from the targeted rare cells. In addition, these cells are separated into at least two sets based upon the number. These sets are detectably distinct from each other and provide an upper and lower indication of the detection ability of the rare cell assay.Type: ApplicationFiled: November 12, 2003Publication date: April 15, 2004Inventors: Galla Chandra Rao, Herman Rutner
-
Publication number: 20010018192Abstract: Stabilized control cells, methods for making the same and kits comprising the stabilized cells are disclosed. Also provided are improved methods for detecting rare cells in biological samples.Type: ApplicationFiled: March 7, 2001Publication date: August 30, 2001Inventors: Leon W.M.M. Terstappen, Galla Chandra Rao, Herman Rutner, Paul A. Liberti
-
Patent number: 5646256Abstract: The present invention is directed to methods for using reagents to generate and stabilize thiols derived from thiol precursors in order to permit more effective reactions with thiol-reactive substances such as liposomes, proteins and antibodies. These methods provide greatly improved conjugates for utilization in various in vivo and in vitro applications.Type: GrantFiled: September 19, 1994Date of Patent: July 8, 1997Assignee: Becton, Dickinson and CompanyInventors: William Shackelford, Josephine Readio, Samuel L. Moore, Herman Rutner
-
Patent number: 5366895Abstract: A method for rapidly lysing liposomes having transition temperatures in the range of 35.degree. to 65.degree. C. is provided. Such liposomes are treated with a surfactant including ##STR1## wherein x represents an average of 9 or 12. The method is applicable to fluorescence immunoassay procedures.Type: GrantFiled: March 5, 1990Date of Patent: November 22, 1994Assignee: Becton, Dickinson and CompanyInventors: Herman Rutner, Abdul M. Butt, Josephine D. Readio, Lewis Pollack
-
Patent number: 5248590Abstract: A liposome reagent encapsulating a molecule to be targeted to a body site or used as an assay reporter has a ligand and a sulfonate-containing group on the liposome surface. Preferred ligands are antibodies or antibody fragments and preferred encapsulants are enzymes or dyes. In the most preferred reagents, the antibody and sulfonate-containing group are covalently bonded to the liposome surface through a connecting group which includes a succinimidyl group resulting from addition of the ligand or sulfonate-containing group to a maleimidyl group. The invention includes a kit of materials for performing an assay using the reagent of the invention as the tracer.Type: GrantFiled: July 22, 1991Date of Patent: September 28, 1993Assignee: Becton, Dickinson and CompanyInventors: Herman Rutner, Josephine D. Readio, Leslie Oppenheimer
-
Patent number: 5164320Abstract: A method for rapidly lysing liposomes having transition temperatures in the range of 35.degree. C. to 65.degree. C. is provided. Such liposomes are treated with a surfactant including polyethyleneglycol mono-n-alkyl ethers such as C.sub.12 H.sub.25 O(CH.sub.2 CH.sub.2 O).sub.n H where n=9-10, a nine mole ethylene oxide adduct of a blend of n-dodecanol, n-tetradecanol and n-hexadecanol, or other appropriate polyethyleneglycol mono-n-alkyl ether capable of causing rapid lysis. The method is applicable to fluorescence immunoassay procedures.Type: GrantFiled: March 5, 1990Date of Patent: November 17, 1992Assignee: Becton, Dickinson and CompanyInventors: Herman Rutner, Abdul M. Butt, Marie M. Sylvestre, Josephine D. Readio, Lewis Pollack
-
Patent number: 4310675Abstract: Monoradioiodinated derivatives of compounds employed in a radioassay prepared from precursors which are either active esters, amino acids, or amines, including a phenolic of imidazole substituent group in which one of the possible two sites on the group for radioiodination is substituted to permit production of a monoradioiodinated derivative. A preferred precursor is an active ester of 3-fluoro-5-radioiodotyrosine which can be coupled to a compound including an amino group to produce a monoradioiodinated derivative of the compound.Type: GrantFiled: May 24, 1979Date of Patent: January 12, 1982Assignee: Becton Dickinson & CompanyInventors: Anandrao S. Akerkar, Herman Rutner
-
Patent number: 4276280Abstract: Derivatives of folic acid wherein the .alpha.-carboxyl group of the glutamyl moiety is substituted with a radical which is capable of being radioiodinated, such as, substituted and unsubstituted tyrosyl and histidyl. The radioiodinated derivatives can be employed as tracers for the assay of folates.Type: GrantFiled: September 29, 1976Date of Patent: June 30, 1981Assignee: Becton, Dickinson and CompanyInventors: Anandrao S. Akerkar, Herman Rutner